India Pharma Outlook Team | Saturday, 21 February 2026
Lonza has greatly expanded its Advanced Synthesis capabilities to facilitate the discovery and development of antibody-drug conjugates (ADCs) and other bioconjugates.
Its ADC technology platform has been incorporated into the Advanced Synthesis portfolio in the global CDMO with its proprietary GlycoConnect technology to conjugate antibodies and its proprietary HydraSpace technology to create polar spacers, as well as a growing range of toxSYN linker payloads.
Site-specific technologies, which are clinically validated and were acquired in 2023 at Synaffix, are meant to enhance the efficacy and tolerability of ADC.
The site has a dual-payload ADC technology with which two complementary cytotoxic molecules can be attached with much accuracy to one antibody with a known amount of payload. The innovation solves the problems of heterogeneity of tumors and resistance to drugs, and provides the development of next-generation ADCs in the Lonza paradigm of end-to-end CDMO, from discovery to clinical supply.
Also Read: Advancing Interventional Radiology in India Through Collaboration
The Netherlands facility, located in the Netherlands, has increased its laboratory capacity to enable it to undertake more R&D work in the field of ADCs and other new forms of bioconjugation modalities such as antibody-oligonucleotide conjugates, targeted lipid nanoparticles and protein-protein conjugates. The location is now providing speedy small-scale bioconjugate prototyping as well as scale-up to provide pilot toxicology material that is supported by improved on-site process and analytical development.
Jan Vertommen, Vice President, Commercial Development, Advanced Synthesis, Lonza, said: “The expansion of the Oss site further reinforces Lonza’s global bioconjugate development and manufacturing network and underscores our dedication to continuously improving our offering and expertise in line with evolving customer and market needs.”
Through these advances, Lonza becomes a company of choice in terms of innovative ADC design, a mix of emerging technologies, dual-payload approaches, and deep knowledge of bioconjugate manufacturing.
